Camlin Fine Sciences Ltd (CAMLINFINE) is currently trading at 80.36 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Camlin Fine Sciences is an India-based manufacturer and exporter of bulk drugs, fine chemicals and food-grade products, operating Food Ingredients and Industrial Products divisions with capabilities in vanillin, antioxidants, APIs and specialty blends, serving processed foods, flavours & fragrances, and industrial end-markets across the Americas, Europe and Asia. Q1 FY27 revenues were INR5,199 million, up approximately 28% year-on-year, driven by robust blends and straights volumes; however, gross margins compressed sharply due to elevated raw material and freight costs, pushing consolidated EBITDA margins well below earlier quarterly levels and prompting management to recalibrate near-term margin guidance. The company is actively ramping commercial vanillin capacity: Q1 sold ~560 tonnes (350 tonnes ethyl vanillin, 200 tonnes methyl vanillin), but utilisation remains suboptimal versus achievable capacity of multiple thousands of tonnes, causing short-term fixed-cost absorption issues and temporary EBITDA dilution in the Aroma segment. Operational actions include a temporary shutdown of the DiPhenol plant due to unfavourable raw material economics, strategic sourcing of intermediates from China for two quarters, insurance settlement of a Brazil fire claim (~INR400 million after haircut) and ongoing liquidation of Europe/China subsidiaries to stop cash burn. Management targets FY27 consolidated revenue of INR2,200–2,300 crores and EBITDA margin of 10–11% (INR220–230 crores of EBITDA), expects improvement to double-digit margins by Q3 if raw material and logistic headwinds moderate, and anticipates short-term working capital support via ~INR100–200 crore external credit lines.

Over the past 52 weeks, Camlin Fine Sciences Ltd has traded between a low of ₹79.00 and a high of ₹202.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Camlin Fine Sciences Ltd has a market capitalization of approximately 1,543.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Camlin Fine Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -23.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,543.69 Cr, Camlin Fine Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Camlin Fine Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Camlin Fine Sciences Ltd is -23.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company announced its Q1 FY27 results on August 11, 2026, for the quarter ended June 30, 2026.

CFSL’s draft OPAS offers €3.60 per Vinpai share, the same price as the November 2025 block acquisition.

CFSL has disclosed an OPAS price of €3.60 per Vinpai share, the same as the block acquisition price.

It filed a draft simplified cash tender offer (OPAS) document with France’s AMF to acquire Vinpai shares it does not already hold.